…
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 158.96M | 2.52M | 63.66M | 36.01M | 47.30M |
| Net income | 124.45M | 9.07M | 52.15M | -5.22M | 37.46M |
| Selling general administrative | 92.45M | 78.65M | 52.79M | 70.06M | 57.48M |
| Gross profit | 220.83M | 120.80M | 88.03M | 196.25M | 214.96M |
| Ebit | 163.68M | 5.55M | 64.32M | 34.21M | 47.35M |
| Ebitda | 197.45M | 42.94M | 101.73M | 3.04M | 98.42M |
| Depreciation and amortization | 33.77M | 37.38M | 37.41M | -31.18M | 51.07M |
| Operating income | 47.20M | 23.02M | 9.82M | 34.21M | 47.35M |
| Other operating expenses | 220.89M | 144.11M | 121.49M | 193.21M | 198.24M |
| Interest expense | 4.71M | 3.04M | 0.66M | -1.80M | -19.63M |
| Income tax expense | 34.51M | -6.55M | 9.84M | 41.23M | 9.84M |
| Total revenue | 268.09M | 167.13M | 131.31M | 196.25M | 277.13M |
| Total operating expenses | 173.63M | 97.78M | 78.20M | 106.14M | 136.06M |
| Cost of revenue | 47.26M | 46.33M | 43.29M | - | 62.18M |
| Total other income expense net | 111.76M | -20.50M | 53.84M | 1.80M | -0.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1560.64M | 941.77M | 787.22M | 762.67M | 1297.59M |
| Intangible assets | 225.44M | 266.65M | 366.90M | 342.45M | 551.04M |
| Other current assets | 30.02M | 22.90M | 3.84M | 8.01M | 10.86M |
| Total liab | 543.42M | 111.33M | 86.30M | 165.18M | 476.43M |
| Total stockholder equity | 1017.21M | 830.44M | 700.91M | 597.49M | 821.16M |
| Other current liab | 31.88M | 33.63M | 12.72M | 84.93M | 16.06M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | 608.09M | 498.98M | 503.02M | 450.86M | 449.09M |
| Good will | 101.54M | 105.25M | 103.37M | 105.67M | 181.21M |
| Cash | 733.52M | 72.31M | 22.95M | 45.01M | 19.52M |
| Total current liabilities | 37.45M | 37.11M | 16.78M | 98.81M | 41.66M |
| Current deferred revenue | - | 1.28M | 1.22M | 8.53M | 11.00M |
| Net debt | -282.03M | -65.20M | -16.79M | 42.74M | 338.39M |
| Short term debt | 1.09M | 1.29M | 0.41M | 0.04M | 6.21M |
| Short long term debt total | 455.69M | 7.11M | 6.17M | 87.75M | 357.91M |
| Other stockholder equity | 400.65M | 337.38M | 197.88M | 147.59M | 372.97M |
| Total current assets | 832.27M | 331.56M | 237.43M | 263.60M | 464.75M |
| Short term investments | 558.59M | 183.86M | 147.35M | 166.86M | 321.59M |
| Net receivables | 59.60M | 38.38M | 39.31M | 30.42M | 85.45M |
| Inventory | 9.13M | 14.11M | 23.97M | 13.29M | 27.33M |
| Accounts payable | 3.24M | 5.23M | 2.43M | 5.31M | 8.40M |
| Accumulated other comprehensive income | 8.46M | -5.94M | -0.82M | -0.98M | -0.92M |
| Non currrent assets other | 198.66M | 202.53M | 5.92M | 14.92M | 29.06M |
| Non current assets total | 728.37M | 610.22M | 549.79M | 499.07M | 832.84M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | -377.32M | -143.66M | -11.68M | - | - |
| Total cash from financing activities | 428.22M | 97.57M | -59.00M | -275.99M | -137.76M |
| Net income | 124.45M | -4.03M | 11.70M | -33.36M | 57.14M |
| Change in cash | 102.62M | 49.35M | -22.05M | 25.48M | -28.44M |
| Begin period cash flow | 72.31M | 22.95M | 45.01M | 19.52M | 47.96M |
| End period cash flow | 174.93M | 72.31M | 22.95M | 25.48M | 19.52M |
| Total cash from operating activities | 49.36M | 97.05M | 48.63M | 137.85M | 78.80M |
| Depreciation | 33.70M | 33.91M | 35.20M | 51.55M | 51.07M |
| Other cashflows from investing activities | -27.44M | -111.75M | 0.42M | - | - |
| Change to inventory | 4.99M | 9.62M | -10.87M | 12.06M | -0.43M |
| Change to account receivables | -21.74M | -6.46M | -4.38M | 55.32M | -28.62M |
| Sale purchase of stock | -15.00M | - | - | - | - |
| Other cashflows from financing activities | -9.77M | -5.14M | -4.55M | -275.94M | 18.00M |
| Capital expenditures | 0.45M | 1.82M | 53.85M | 17.92M | 8.76M |
| Change in working capital | -12.66M | 19.36M | -34.40M | 64.04M | -59.58M |
| Stock based compensation | 46.85M | 41.09M | 25.74M | 60.28M | 38.78M |
| Other non cash items | -118.81M | 6.73M | 10.39M | -25.38M | - |
| Free cash flow | 48.91M | 95.23M | -5.22M | 119.93M | 70.04M |
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| DOGEF Orsted A/S |
0.13 0.62% |
21.25 | 28.82 | 0.66 | 6.50 | 0.07 |
| TBB AT&T Inc. 5.35% GLB NTS 66 |
- -% |
17.63 | 4.60 | - | - | - |
| CCZ Comcast Holdings Corp |
- -% |
62.32 | 55.07 | - | - | - |
| STMZF Scottish Mortgage Investment Trust PLC |
-0.12 0.63% |
19.72 | - | - | 2.56 | - |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Todd C. Davis Ph.D. | CEO & Director | 1961 |
| Mr. Octavio Espinoza | Chief Financial Officer | 1971 |
| Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary | 1975 |
| Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development | NA |
| Ms. Melanie J. Herman CPA | Executive Director of Investor Relations and Financial Planning & Analysis | 1979 |
| Ms. Marjorie Fackovec | Head of People Operations | NA |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology & Scientific Affairs | NA |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations & QA - Capitsol | 1969 |
| Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy | 1950 |
| Mr. Richard B. Baxter | Senior VP of Investment Operations | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.